
The new substrate is synthetically easily accessible

FIG. 1

25x10° Enzymatic fragmentation can take place to the - No beta-lactamese Adding beta-lactamase new substrate



Synthesis of RECTO

FIG. 3




FIG A

Remaining Substrate 0.8 0.6-0.2 1500 3000 Time (min) $_{1/2}$ = 182 hours in PBS buffer 4500 6000

Sulfoxide increases substrate stability




FIG. 6

ļa

ŀ÷

12

cephalosporin-phenol ethers that we wish to claim:

$$\begin{matrix} R & \begin{matrix} H \\ N \end{matrix} & \begin{matrix} A \\ O \end{matrix} & \begin{matrix} A \end{matrix} & \begin{matrix} Z \end{matrix} & \begin{matrix} CO_2R' \end{matrix}$$


Preferred R = benzyl, 2-thienylmethyl, or cyanomethyl; A = S or SO; R' = H or physiologically acceptable salts or ester groups.

where Z can be:

(I)
$$X$$
 where $X = H, F, Cl, Br, CO_2R^*$; $Y = N, CH, C \cdot CN, C \cdot CF_3$ (II) X where $X = H, F, Cl, Br, CO_2R^*$; $Y = N, CH, C \cdot CN, C \cdot CF_3$ (III) X X X $Y = N, CH, C \cdot CN, C \cdot CF_3$ (IV) X $Y = N, CH, C \cdot CN, C \cdot CP_3$ (IV) X $Y = N, CH, C \cdot CN, C \cdot CP_3$ (IV) X $Y = N, CH, C \cdot CN, C \cdot CP_3$ (IV) X $Y = N, CH, C \cdot CN, C \cdot CP_3$ (IV) X $Y = N, CH, C \cdot CN, C \cdot CP_3$ (IV) X $Y = N, CH, C \cdot CN, C \cdot CP_3$ (IV) X $Y = N, CH, C \cdot CN, C \cdot CP_3$ (IV) X $Y = N, CH, C \cdot CN, C \cdot CP_3$ (IV) X $Y = N, CH, C \cdot CN, C \cdot CP_3$ (IV) X $Y = N, CH, C \cdot CN, C \cdot CP_3$ (IV) X $Y = N, CH, C \cdot CN, C \cdot CN, C \cdot CP_3$ (IV) X $Y = N, CH, C \cdot CN, C \cdot CN, C \cdot CP_3$ (IV) X $Y = N, CH, C \cdot CN, C \cdot CN,$

FIG. 7

Resorufin-cephalosporin cleaved by β-lactamase



Absorption spectra of resorufin-cephalosporin before and after β -lactamase treatment




FIG. 10